| Biomarker ID | 968 |
| PMID | 22870216 |
| Year | 2012 |
| Biomarker | GADD45B; CDKN1A; NLRP1; ERBB3; FMO5; SERINC2; AMFR; DPP4; PGC; YWHAE; EHF; TF; TNFSF10; EIF5A; TGM4; |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Relapse: [GADD45B (4.86 fold); CDKN1A (2.65 fold); NLRP1 (1.57 fold)]; Downregulated in Relapse: [ERBB3 (0.55 fold); FMO5 (0.55 fold); SERINC2 (0.43 fold); AMFR (0.41 fold); DPP4 (0.40 fold); PGC (0.38 fold); YWHAE (0.34 fold); EHF(0.33 fold); TF (0.33 fold); TNFSF10 (0.31 fold); EIF5A (0.15 fold); TGM4 (0.03 fold);] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Relpase Vs No Relapse |
| Type of Biomarker | Prognostic |
| Cohort | Two methods were employed to define genes differentially expressed in stroma of high and low risk cases. GSE8218 was used as PAM analysis to divide patients into 2 groups: Aggressive prostate cancer was defined as patients who experienced relapse within 1 year (n=40), and indolent (less agrresive) as those patients who either relapsed later than 4 years after surgery or who did not relapse and had at least 4 years’ follow-up data available. (n=9). Secondly, same data set was used to identify probe sets that correlate with disease-free survival time, including patients that relapsed between one and four years after surgery. 19 probes that were common to both were selected. 47 independent test samples including 36 samples from data set GSE8218 and 11 samples from data set GSE17951. |
| Senstivity | Training: 88.9 ; Testing: [31 High risk (HR) Stroma: 87.1%; 2 HRs with <10% tumor: 100%; 7 HRs stroma: 85.7%; 2 HRs with <10% tumor: 100%;] |
| Specificity | Training: 88.9 ; Testing: [3 LRs with <10% tumor: 100%;100%; 2 LRs with <10% tumor: 50%] |
| AUC | NA |
| Accuracy | Training: 88.9 ; Testing: [31 High risk (HR) Stroma: 87.1%; 2 HRs with <10% tumor: 100%; 3 LRs with <10% tumor: 100%; 7 HRs stroma: 85.7%; 2 HRs with <10% tumor: 100%; 2 LRs with <10% tumor: 50%] |
| Level Of Significance | p<0.05 |
| Method Used | Affymetrix GeneChips (GSE17951: U133 Plus 2.0 platform; GSE8218: U133A platform) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent dataset |
| Technical Name | GADD45B, CDKN1A, NLRP1, ERBB3, FMO5, SERINC2, AMFR, DPP4, PGC, YWHAE, EHF, TF, TNFSF10, EIF5A, TGM4 |